1-8 of 8
Ulrik B. Nielsen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells

Defne Yarar, Johanna Lahdenranta, William Kubasek, Ulrik B. Nielsen, Gavin MacBeath
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (9): 2072–2080.
https://doi.org/10.1158/1535-7163.MCT-15-0075
Published: 02 September 2015
View article titled, Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Open the PDF for Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Elena Geretti, Shannon Curtis Leonard, Nancy Dumont, Helen Lee, Jinzi Zheng, Raquel De Souza, Daniel F. Gaddy, Christopher W. Espelin, David A. Jaffray, Victor Moyo, Ulrik B. Nielsen, Thomas J. Wickham, Bart S. Hendriks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (9): 2060–2071.
https://doi.org/10.1158/1535-7163.MCT-15-0314
Published: 02 September 2015
View article titled, Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Open the PDF for Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302) in another window
Includes: Supplementary data
Journal Articles

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

Jeffrey D. Kearns, Raghida Bukhalid, Mark Sevecka, Gege Tan, Nastaran Gerami-Moayed, Shannon L. Werner, Neeraj Kohli, Olga Burenkova, Callum M. Sloss, Anne M. King, Jonathan B. Fitzgerald, Ulrik B. Nielsen, Beni B. Wolf
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (7): 1625–1636.
https://doi.org/10.1158/1535-7163.MCT-14-0772
Published: 06 July 2015
View article titled, Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Open the PDF for Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic in another window
Includes: Supplementary data
Journal Articles

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Jian Tang, Victoria Rimkunas, Lihui Xu, Neeraj Kohli, Rachel Rennard, Maja Razlog, Yang Jiao, Brian D. Harms, Kenneth J. Olivier, Jr, Birgit Schoeberl, Ulrik B. Nielsen, Alexey A. Lugovskoy
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (2): 410–425.
https://doi.org/10.1158/1535-7163.MCT-13-0255
Published: 09 February 2014
View article titled, MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Open the PDF for MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors in another window
Includes: Supplementary data
Journal Articles

Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies

Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou, Jianlong Lou, Fraser Conrad, Gregory P. Adams, Birgit Schoeberl, Ulrik B. Nielsen, James D. Marks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1467–1476.
https://doi.org/10.1158/1535-7163.MCT-11-1038
Published: 05 July 2012
View article titled, Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Open the PDF for Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms, Sharlene Adams, Violette Paragas, Shinji Oyama, Bo Zhang, Lia Luus, Ryan Overland, Stephanie Nguyen, Jinming Gu, Neeraj Kohli, Matt Wallace, Michael J. Feldhaus, Arthur J. Kudla, Birgit Schoeberl, Ulrik B. Nielsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 582–593.
https://doi.org/10.1158/1535-7163.MCT-11-0820
Published: 06 March 2012
View article titled, Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Open the PDF for Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 in another window
Includes: Supplementary data
Journal Articles

Abstract A144: Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic.

Shannon L. Werner, Gege Tan, Jeffrey D. Kearns, Anne M. King, Callum Sloss, Nastaran Gerami-Moayed, Raghida Bukhalid, Ulrik B. Nielsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A144.
https://doi.org/10.1158/1535-7163.TARG-11-A144
Published: 12 November 2011
View article titled, Abstract A144: Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic.
Journal Articles

Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR.

Gege Tan, Jeffrey D. Kearns, Nastaran Gerami-Moayed, Neeraj Kohli, Shannon L. Werner, Anne M. King, Callum M. Sloss, Raghida Bukhalid, Ulrik B. Nielsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A210.
https://doi.org/10.1158/1535-7163.TARG-11-A210
Published: 12 November 2011
View article titled, Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR.